Get Premium to unlock powerful stock data

5 Health Care Companies Gurus Are Buying

These popular stocks have positions in several gurus' portfolios

Author's Avatar
Sep 05, 2017
Article's Main Image

According to the GuruFocus All-In-One Screener, the following health care stocks have positions in gurus' portfolios.

Twenty-three gurus hold shares of Shire PLC ADR (

SHPG, Financial).

The biotechnology company's brands include Vyvanse, Lialda and Adderall XR.

The company has a market cap of $46.12 billion; the stock is trading with a price-earnings (P/E) ratio of 56.90. The price of $151.84 is 27.43% below its 52-week high and 8.96% above its 52-week low. Over the past decade, it has returned a gain of 93%.

During the second quarter, 

Leon Cooperman (Trades, Portfolio) added 2.65% to his position and Mario Gabelli (Trades, Portfolio) increased his holding by 15.22%.

Three gurus own shares of Amicus Therapeutics Inc. (

FOLD, Financial).

The biopharmaceutical company develops treatments for a range of rare and orphan diseases.

The company has a market cap of $2.36 billion. The price of $14.32 is 0.28% below its 52-week high and 224.72% above its 52-week low. Over the past decade, it has returned a gain of 18%.

During the second quarter, 

Joel Greenblatt (Trades, Portfolio) and Paul Tudor Jones  (Trades, Portfolio) established positions in the company.

Twenty-four gurus are shareholders of Amgen Inc. (

AMGN, Financial).

The company has a market cap of $130.4 billion; the stock is trading with a P/E ratio of 16.20. The price of $178.71 is 2.99% below its 52-week high and 33.72% above its 52-week low. Over the past decade, it has returned a gain of 248%.

During the second quarter, 

Richard Pzena (Trades, Portfolio) added 3.24% to his position and Ken Fisher (Trades, Portfolio) increased his holding by 2.86%.

Twenty-six gurus own  shares of Gilead Sciences Inc. (

GILD, Financial).

The biopharmaceutical company develops treatments for a variety of underserved ailments, including HIV and hepatitis B and C.

The company has a market cap of $109.37 billion; the stock is trading with a P/E ratio of 9.08. The price of $83.75 is 0.45% below its 52-week high and 31.358.96% above its 52-week low. Over the past decade, it has returned a gain of 351%.

During the second quarter, the 

T Rowe Price Equity Income Fund (Trades, Portfolio) added 27.77% to its position and John Rogers (Trades, Portfolio) increased his holding by 16.41%. Fisher increased his stake by 1.89%.

Three gurus own shares of Neurocrine Biosciences Inc. (

NBIX, Financial).

The biotechnology company develops drugs to treat neurological and endocrine-related diseases.

The company has a market cap of $5.03 billion. The price of $57.01 is 0.40% below its 52-week high and 52.64% above its 52-week low. Over the past decade, it has returned a gain of 476%.

George Soros (Trades, Portfolio) established a positon in the company during the second quarter.

Disclosure: I do not own any shares of any stocks mentioned in this article.

Also check out:
Rating:
0 / 5 (0 votes)

GuruFocus Screeners

Related Articles